Investigational Drug Information for SGN-CD19A
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug SGN-CD19A?
SGN-CD19A is an investigational drug.
There have been 80 clinical trials for SGN-CD19A. The most recent clinical trial was a Phase 3 trial, which was initiated on September 30th 2022.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Hodgkin Disease. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and Millennium Pharmaceuticals, Inc.
There are one hundred and fifty-four US patents protecting this investigational drug and two international patents.
Summary for SGN-CD19A
|US Patent Applications||633|
|WIPO Patent Applications||496|
|Japanese Patent Applications||166|
|Clinical Trial Progress||Phase 3 (2022-09-30)|
Recent Clinical Trials for SGN-CD19A
|A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors||Seagen Inc.||Phase 1|
|A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma||Takeda||Phase 4|
|A Study of SGN-ALPV in Advanced Solid Tumors||Seagen Inc.||Phase 1|
Clinical Trial Summary for SGN-CD19A
Top disease conditions for SGN-CD19A
Top clinical trial sponsors for SGN-CD19A
US Patents for SGN-CD19A
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGN-CD19A||See Plans and Pricing||Method for the diagnosis, prognosis and treatment of lung cancer metastasis||Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES)||See Plans and Pricing|
|SGN-CD19A||See Plans and Pricing||Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|SGN-CD19A||See Plans and Pricing||Peptidomimetic macrocycles as modulators of MCL-1||AILERON THERAPEUTICS, INC. (Cambridge, MA)||See Plans and Pricing|
|SGN-CD19A||See Plans and Pricing||Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors||AbbVie Inc. (North Chicago, IL)||See Plans and Pricing|
|SGN-CD19A||See Plans and Pricing||Compositions comprising bacterial strains||4D Pharma Research Limited (GB)||See Plans and Pricing|
|SGN-CD19A||See Plans and Pricing||Compositions comprising bacterial strains||4D Pharma Research Limited (Aberdeen, GB)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
International Patents for SGN-CD19A
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SGN-CD19A||Australia||AU2013273242||2032-06-06||See Plans and Pricing|
|SGN-CD19A||Australia||AU2019204269||2032-06-06||See Plans and Pricing|
|SGN-CD19A||Canada||CA2875918||2032-06-06||See Plans and Pricing|
|SGN-CD19A||China||CN104603288||2032-06-06||See Plans and Pricing|
|SGN-CD19A||Denmark||DK2859120||2032-06-06||See Plans and Pricing|
|SGN-CD19A||European Patent Office||EP2859120||2032-06-06||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|